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BRD4 governs pathological cardiac gene expres-
sion by binding acetylated chromatin, resulting in
enhanced RNA polymerase II (Pol II) phosphorylation
and transcription elongation. Here, we describe a
signal-dependent mechanism for the regulation of
BRD4 in cardiomyocytes. BRD4 expression is sup-
pressed by microRNA-9 (miR-9), which targets the
30 UTR of the Brd4 transcript. In response to stress
stimuli, miR-9 is downregulated, leading to derepres-
sion of BRD4 and enrichment of BRD4 at long-range
super-enhancers (SEs) associated with pathological
cardiac genes. A miR-9 mimic represses stimulus-
dependent targeting of BRD4 to SEs and blunts
Pol II phosphorylation at proximal transcription start
sites, without affecting BRD4 binding to SEs that
control constitutively expressed cardiac genes.
These findings suggest that dynamic enrichment of
BRD4 at SEs genome-wide serves a crucial role in
the control of stress-induced cardiac gene expres-
sion and define a miR-dependent signaling mecha-
nism for the regulation of chromatin state and Pol II
phosphorylation.
INTRODUCTION
In response to diverse insults, the heart undergoes pathological
remodeling, a process often characterized by cardiomyocyte
hypertrophy, which contributes to contractile dysfunction and
heart failure. Abnormalities in the control of gene expression
are central to the pathogenesis of cardiac hypertrophy and heart
failure (Kao et al., 2015; Lowes et al., 2002). A defined set
of sequence-specific DNA-binding transcription factors (e.g.,
NFAT, GATA4, and MEF2) have been shown to be recruited to1366 Cell Reports 16, 1366–1378, August 2, 2016 ª 2016 The Author
This is an open access article under the CC BY-NC-ND license (http://regulatory regions of the genome to trigger aberrant myocardial
gene transcription by RNA polymerase II (Pol II) (Sano and
Schneider, 2004; Sayed et al., 2013; van Berlo et al., 2013).
Epigenetic events are also crucially involved in stress-dependent
activation of pathological cardiac gene expression (Gillette and
Hill, 2015; Mayer et al., 2015; Preissl et al., 2015; Renaud
et al., 2015). For example, dynamic changes in N-ε-acetylation
of lysine side chains on nucleosomal histone tails are observed
during cardiac hypertrophy, and genetic and pharmacological
manipulations of histone acetyltransferases and histone deace-
tylases have profound effects on pro-hypertrophic gene expres-
sion in cardiomyocytes (McKinsey, 2012; Xie and Hill, 2013).
Recently, a member of a family of epigenetic reader molecules
called bromodomain and extraterminal (BET) acetyl-lysine bind-
ing proteins was shown to control pathological cardiac gene
expression and cardiac hypertrophy (Haldar and McKinsey,
2014). JQ1, a first-in-class, potent, and specific inhibitor of
BET bromodomains that functions by competitively displacing
BET proteins from acetylated-histones (Filippakopoulos et al.,
2010), was found to block agonist-dependent hypertrophy of
cultured cardiomyocytes and also to inhibit pressure overload-
mediated left ventricular (LV) hypertrophy in mice (Anand et al.,
2013; Spiltoir et al., 2013). The anti-hypertrophic effect of JQ1
was recapitulated by genetic knockdown of a single BET family
member, BRD4, implicating this reader protein as a nodal
regulator of pathological gene expression in cardiomyocytes
(Anand et al., 2013). BRD4 is thought to regulate cardiac gene
expression through interactions with the positive transcription
elongation factor b (P-TEFb) complex (Haldar and McKinsey,
2014). BRD4 associates with active, hyper-acetylated regions
of regulatory chromatin via its acetyl-lysine recognition modules
(bromodomains) and consequently activates Pol-II-dependent
transcription through associationwith cyclin-dependent kinase 9
(CDK9), a key component of P-TEFb (Bisgrove et al., 2007; Jang
et al., 2005; Yang et al., 2005). CDK9-mediated Pol II phosphor-
ylation at transcription start sites (TSS) facilitates Pol II pause
release and productive transcription elongation. In non-cardiac(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
cells, BRD4 has also been shown to disproportionately associate
with a subset of cell state-specific enhancers called super-en-
hancers (SEs) (Brown et al., 2014; Chapuy et al., 2013; Di Micco
et al., 2014; Love´n et al., 2013), which signal via long-range
genomic interactions to regulate state-specific transcription pro-
grams from core promoters (Hnisz et al., 2013, 2015; Whyte
et al., 2013).
The existence of BRD4-enriched SEs in cardiomyocytes has
yet to be established. Furthermore, it is unclear whether BRD4
functions as a stress-responsive co-factor in the heart. Here,
we define a microRNA (miR)-dependent signaling circuit in car-
diomyocytes that controls dynamic recruitment of BRD4 to
distinct genomic regulatory loci in response to pro-hypertrophic
signals. In unstimulated cardiomyocytes, BRD4 protein abun-
dance is restrained by miR-9. In response to stress stimuli,
miR-9 expression is downregulated, allowing for selective tar-
geting of BRD4 to cardiomyocyte SEs and promoters that regu-
late hypertrophic gene expression. Introduction of a miR-9
mimic into cardiomyocytes blunts signal-dependent recruitment
of BRD4 to these cis-acting elements, leading to suppression of
Pol II phosphorylation at associated TSSs and repression of
downstream gene expression. In contrast, miR-9 does not alter
BRD4 binding to SEs and promoters for constitutively ex-
pressed cardiac genes or genes that are downregulated in
response to hypertrophic stimuli. These findings reveal an
epigenetic signaling pathway that couples upstream cues to
transcriptional outputs that drive pathological cardiac remodel-
ing and heart failure pathogenesis.
RESULTS
miR-9 Targets BRD4 in Cardiomyocytes
We previously observed that increased BRD4 protein abun-
dance during cardiac hypertrophy occurs without concomitant
elevation of BRD4 mRNA (Anand et al., 2013; Spiltoir et al.,
2013; Stratton and McKinsey, 2015), suggesting the possibility
that cardiac BRD4 is post-transcriptionally controlled by a
microRNA (miR). Indeed, in silico analysis of the Brd4 mRNA
30 UTR revealed four conserved binding sequences for six candi-
date miRs (miR-141, miR-200a, miR-124, miR-204, miR-211,
andmiR-9) (Figure 1A). We reasoned that a putative miR that tar-
gets BRD4 should be downregulated during hypertrophic stress
(Figure 1B). As shown in Figure 1C, stimulation of neonatal rat
ventricular myocytes (NRVMs) with the hypertrophic agonist
phenylephrine (PE) failed to reduce expression of miR-141,
miR-200a, miR-124, miR-204, or miR-211, arguing against roles
for these miRs in the stress-coupled accumulation of BRD4 in
the heart. In contrast, miR-9 was significantly downregulated in
PE-treated cardiomyocytes in vitro (Figure 1C). Agonist-induced
downregulation of miR-9 in cardiomyocytes was dependent
on histone deacetylase (HDAC) catalytic activity (Figure 1D).
miR-9 expression was also reduced in cultured cardiomyocytes
stimulated with an independent hypertrophic agonist, prosta-
glandin F2a (PGF2a), and in vivo in rodent pressure overload
models of left ventricular (LV) and right ventricular (RV) patholog-
ical cardiac hypertrophy (Figures 1E and 1F). In addition, me-
chanical unloading of failing human hearts with left ventricular
assist devices (LVADs), which led to reversal of cardiac hypertro-phy and improvement of systolic function in this patient cohort
(Ambardekar et al., 2011), was associated with increased LV
expression of miR-9, and this correlated with reduced levels of
BRD4 protein in the myocardium (Figures 1G and 1H). The
7-mer-m8 target sequence for miR-9 in the Brd4 30UTR is
conserved in human, mouse, and rat (Figure 1I). Together, these
data are consistent with the hypothesis that downregulation of
miR-9 is a conserved mechanism for derepression of BRD4 in
response to signals for pathological cardiac hypertrophy.
We next tested whether miR-9 could directly target BRD4.
Transfection of miR-9 mimic into NRVMs led to a marked reduc-
tion of BRD4 protein abundance, which was comparable to the
effect of directly targeting BRD4 transcripts with small interfering
RNA (siRNA) (Figures 2A and S1A). Importantly, miR-9 mimic did
not reduce expression of a closely related BET family member,
BRD2, establishing the specificity of the observed decrease in
BRD4 abundance. Conversely, blockade of endogenous miR-9
through transfection of amiR-9 inhibitor (anti-miR-9) into NRVMs
increased endogenous BRD4 protein levels relative to control
anti-miR, again without influencing BRD2 expression (Fig-
ure S1B). In addition, miR-9 mimic, but not control mimic, signif-
icantly reduced expression of a luciferase reporter harboring the
30 UTR of rat Brd4, a silencing effect that was lost upon mutation
of the conserved miR-9 target sequences in the 30UTR (Fig-
ure 2B). Hence, miR-9 can directly suppress BRD4 protein
abundance.
miR-9 and Small Molecule BET Bromodomain Inhibitor,
JQ1, Target Overlapping Cardiac Gene Programs
Cardiomyocyte hypertrophy is blocked by the small molecule
BET inhibitor, JQ1, or by genetic knockdown of BRD4 (Anand
et al., 2013; Spiltoir et al., 2013). To address the hypothesis
that JQ1 and miR-9 exert overlapping effects on cardiomyocyte
gene expression via common targeting of BRD4, whole tran-
scriptome analysis using RNA-seq was performed in NRVMs.
NRVMs were transfected with miR-9 mimic or control mimic
and were either left untreated or stimulated with PE for 48 hr
(Figure 3A). Introduction of miR-9 mimic led to a significant
reduction in NRVM hypertrophy (Figures 3B and 3C). Further-
more, the miR-9 mimic reversed many PE-mediated changes
in gene expression, as illustrated by the heatmap (Figure 3D;
Data S1). Comparison of changes in cardiomyocyte gene
expression elicited by miR-9 mimic and JQ1 revealed significant
overlap (Figure 3E). Functional pathway analysis demonstrated
that a broad range of biological processes related to pathologic
hypertrophy were similarly controlled by miR-9 and JQ1.
Notably, the general patterns of reversing PE-induced growth
and inflammation pathways, while rescuing expression of path-
ways associated with fatty acid oxidation metabolism, were
observed (Data S2 and S3). As shown in Figure 3F, qPCR
from independent samples confirmed that miR-9 mimic blunts
expression of PE-inducible genes that are canonically associ-
ated with pathological cardiac hypertrophy (Nppa, Nppb, and
Xirp2) and cardiac fibrosis (Ctgf and TSC22D1), consistent
with observed effects of JQ1 (Anand et al., 2013; Spiltoir
et al., 2013). PE-induced expression of these transcripts was
also reduced in cardiomyocytes in which BRD4 expression
was knocked down using short hairpin RNA (shRNA) (Figure S2).Cell Reports 16, 1366–1378, August 2, 2016 1367
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Figure 1. Cardiac miR-9 Expression Is Suppressed during Pathological Hypertrophy
(A) Schematic representation of the rat BRD4 30UTR with predicted microRNA (miR) binding sites indicated.
(B) Hypothesis that signals for cardiac hypertrophy repress expression of a BRD4-targeting miR.
(C) Expression of putative BRD4 30 UTR binding miRs in neonatal rat ventricular myocytes (NRVMs) treated with vehicle control (Veh) or the pro-hypertrophic
agonist phenylephrine (PE; 10 mM) for 48 hr. Only miR-9 expression was significantly downregulated.
(D) Treatment with the histone deacetylase inhibitor (HDACi) AR-42 (500 nM) derepressed miR-9 expression in PE-treated NRVMs.
(E and F) miR-9 expression was also significantly downregulated in NRVMs treated with prostaglandin F2a (PGF2a; 10 mM) for 48 hr (E), in hypertrophic left
ventricles (LV) of mice subjected to transverse aortic constriction (TAC), and in hypertrophic right ventricles (RV) of rats with pulmonary hypertension due to
combined exposure to hypoxia and the VEGF receptor inhibitor SU5416 (F). *p < 0.05 versus vehicle or sham operated or normoxic (Nx) controls.
(G and H) Expression of miR-9 was significantly increased in human hearts upon mechanical unloading with a left ventricular assist device (LVAD) (G), which
correlated with reduced BRD4 protein expression in the LV (H). *p < 0.05 versus Pre-LVAD.
(I) Conservation of the miR-9 binding site in human, mouse, and rat BRD4 30UTR.Together, these findings support the hypothesis that downregu-
lation of miR-9 in response to a hypertrophic agonist allows for
increased BRD4 activity, which subsequently promotes patho-
logical cardiac gene expression.1368 Cell Reports 16, 1366–1378, August 2, 2016Dynamic Recruitment of BRD4 to Cardiomyocyte
Super-Enhancers Is Suppressed by miR-9
Although inhibition of BRD4 has defined a role for this protein as
a positive regulator of cardiac hypertrophy, the extent to which
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Figure 2. Cardiac BRD4 Expression Is Suppressed by miR-9
(A) NRVMs were transfected with the indicated siRNAs, microRNA mimics,
microRNA inhibitors, or controls (Ctrl), and 48 hr post-transfection protein
homogenates were analyzed by immunoblotting with the indicated antibodies;
two independent anti-BRD4 antibodies were employed (Ab #1 and Ab #2), as
described in the Experimental Procedures. The miR-9 mimic reduced
expression of BRD4 as efficiently as a BRD4-targeting siRNA; calnexin served
as a loading control.
(B) HEK293 cells were transfected with luciferase reporters fused to wild-type
ratBrd4 30 UTR orBrd4 30UTR containing a point mutation at themiR-9 binding
site. Cells were co-transfected with either miR-9 mimic or control, and lucif-
erase activity was quantified 24 hr post-transfection. *p < 0.05 versus Ctrl
mimic transfected cells.
See also Figure S1.this chromatin reader is subject to signal-dependent control in
cardiomyocytes is unclear. In particular, it is not known if
genomic enrichment of cardiomyocyte BRD4 changes under hy-
pertrophic stress, or whether it is affected by miR-9. To address
these questions, we subjected NRVMs to whole-genome chro-
matin immunoprecipitation sequencing (ChIP-seq) to dynami-
cally map gene regulatory elements bound by BRD4. NRVMs
were transfected with miR-9 mimic or control mimic and were
either left untreated or stimulated with PE for 48 hr. Chromatin
immunoprecipitation (ChIP) was performed with a BRD4-
specific antibody, and associated cardiomyocyte DNA was sub-
ject to deep sequencing (Figure 4A). Well-defined peaks of
enhancer-associated BRD4 were mapped throughout the cardi-
omyocyte genome (Figure 4B). Aggregate analysis of the three
treatment groups (unstimulated + control miR mimic, PE + con-
trol miR mimic and PE + miR-9 mimic) revealed prominent BRD4
binding to 3,771 gene enhancers, with enhancers defined as be-
ing at least 500 base pairs from the TSS of the associated gene.To assess signal- and miR-9-dependent regulation of BRD4
genomic localization, subsequent analysis focused on SEs,
which are long-range gene regulatory elements that have been
defined in cancer and immune cells based on abundant BRD4
binding above a threshold level found at typical enhancers
(TEs) (Brown et al., 2014; Chapuy et al., 2013; Love´n et al.,
2013). Four hundred and fifty-nine BRD4-enriched SEs were de-
tected in cardiomyocytes (Figure 4C). Cardiomyocyte SEs were
ranked by change in BRD4 enrichment following PE treatment
relative to unstimulated cells, and three general patterns of
BRD4 dynamics were observed: (1) increased BRD4 binding
with PE, (2) loss of BRD4 binding with PE, and (3) constitutive
BRD4 binding that is unchanged by PE stimulation (Figure 4C).
Using a 1.5-fold change threshold, BRD4 association was found
to be increased at 65 SEs and reduced at 19 SEs in response to
PE treatment (Figure 4D). miR-9 mimic blocked PE-mediated
recruitment of BRD4 to SEs, while having no significant effect
on agonist-dependent depletion of BRD4 from SEs or constitu-
tive binding of BRD4 to basal SEs (Figures 4D and S3). BRD4
binding to SEs for the Nppa, Nppb, and Ctgf genes was dramat-
ically enhanced by PE stimulation and blunted by miR-9 mimic,
while high level constitutive binding of BRD4 to SEs for the phos-
pholamban (Pln), and myosin heavy chain (Myh) 6/7 genes was
unaffected by PE or miR-9 mimic (Figure 4E). These findings
reveal the existence of dynamic BRD4-enriched SEs in cardio-
myocytes and suggest that miR-9-regulated BRD4 protein is
preferentially recruited to a subset of hyper-activated SEs in
response to hypertrophic stimuli.
Bioinformatic analyseswere performed to begin to address the
mechanism by which hypertrophic agonists stimulate recruit-
ment of BRD4 to distinct genomic loci in cardiomyocytes.
Genome coordinates for the 65 SEs where BRD4 abundance
was increased following PE treatment were enriched for AP-1
transcription factor family binding sites relative to randomly
selected genomic sequences of similar length (Figure 5A). In
contrast, there was no enrichment of AP-1 binding sites in SEs
where BRD4 binding was reduced by PE treatment (not shown).
To test the hypothesis that AP-1 transcription factors facilitate
recruitment of BRD4 toSEs in response to hypertrophic agonists,
we employed adenovirus encoding a mutant form of c-Fos that
functions as a broad-spectrum dominant-negative inhibitor of
the AP-1 family (dnAP-1) (Olive et al., 1997). SE1 and SE2 up-
stream of the Ctgf TSS (Figure 5B) were selected for anti-BRD4
ChIP-PCR analysis because they contain AP-1 binding sites
andwere bound by an increased amount of BRD4 upon PE treat-
ment (Figure 4C). As shown in Figure 5C, BRD4 association with
these SEs was significantly reduced in cardiomyocytes express-
ing dn-AP1 compared to control cells infected with adenovirus
encoding b-galactosidase. Furthermore, diminished BRD4 tar-
geting to SE1 and SE2 in dn-AP-1-expressing cardiomyocytes
correlated with reduced expression of Ctgf mRNA, suggesting
that AP-1-mediated recruitment of BRD4 to these sites is
required for downstream target gene expression (Figure 5D).
miR-9 Blunts Stimulus-Dependent BRD4 Binding and
Pol II Phosphorylation at Cardiac Gene Promoters
SEs are thought to signal to proximal promoters to stabilize
BRD4-containing coactivator complexes near TSSs, therebyCell Reports 16, 1366–1378, August 2, 2016 1369
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(A) NRVMs were transfected with control mimic (Ctrl; 25 nM) or miR-9 mimic (25 nM), and 24 hr post-transfection cells were treated with vehicle (Veh) or
phenylephrine (PE; 10 mM) for 48 hr. RNA was harvested for RNA-seq.
(B and C) NRVMs transfected with miR-9 mimic appeared smaller relative to controls (B), and quantitative assessment of cell size confirmed that miR-9 mimic
significantly blunted PE-induced hypertrophy (C) (n = 24 per group; *p < 0.05 versus Ctrl). Scale bar, 100 mm.
(D) Heatmap summary of NRVM gene expression in the indicated treatment groups. Gene expression patterns were categorized based on responses to PE and
miR-9 mimic.
(E) miR-9 mimic-dependent gene expression changes were compared to changes seen with BET protein inhibition using JQ1. The Venn Diagrams indicate
significant alterations in gene expression mediated by miR-9 mimic and JQ1 treatment, with both treatments blunting induction of gene expression by PE, and
rescuing expression of genes that are suppressed by PE.
(F) qPCR confirmed that miR-9 mimic inhibits PE-induced expression of prototypical pathological cardiac genes (n = 3 per treatment group; *p < 0.05).
See also Figure S2 and Data S1, S2, and S3.
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Figure 5. AP-1 Function Is Required for Stimulus-Coupled Recruit-
ment of BRD4 to Ctgf SEs
(A) Analysis of PE-inducible, BRD4-enriched SE sequences revealed enrich-
ment of the indicated, predicted transcription factor binding sites. Binding
sites for members of the AP-1 transcription factor family were over-
represented.
(B) To test the hypothesis that AP-1 facilitates recruitment of BRD4 to SEs for
pro-hypertrophic genes, NRVMs were infected with adenoviruses encoding
dominant-negative AP-1 (Ad-dnAP-1) or b-galactosidase control (Ad-b-Gal).
After 48 hr of PE treatment, sheared chromatin was subjected to anti-BRD4
ChIP, followed by PCR to quantify the presence of SE1 and SE2 of the Ctgf
locus, as indicated.
(C and D) Expression of dnAP-1 significantly reduced the abundance of
BRD4 at these SEs (C), which correlated with suppression of Ctgf mRNA
expression (D). *p < 0.05 versus Ad-b-Gal.facilitating p-TEFb-mediated Pol II phosphorylation and tran-
scription elongation (Arner et al., 2015; Brown et al., 2014; Pnueli
et al., 2015). ChIP-seq data were further analyzed to assess(C) A total of 459 SEs, defined by BRD4 signal breadth and intensity, are plotted
(D) Box plots of BRD4 binding to SEs, categorized as PE-induced, PE-reduced,
change (unchanged). miR-9mimic blunted BRD4 recruitment to PE-induced SEsw
failed to significantly attenuate PE-mediated release of BRD4 binding from certa
(E) Enhancers and SEswere ranked by BRD4 signal intensity. PE treatment drama
genes, and miR-9 mimic blocked BRD4 recruitment to these SEs. BRD4 bind
significantly altered by PE or miR-9 mimic.
See also Figure S4 and Data S4.
1372 Cell Reports 16, 1366–1378, August 2, 2016whether PE and/or miR-9 alter BRD4 binding to cardiomyocyte
gene promoters. To define promoters, ChIP-seq was performed
with a total Pol II-specific antibody. Upon overlay of the BRD4
ChIP-seq data, 422 cardiomyocyte promoters were found to
be co-occupied by Pol II and BRD4. Similar to SE analysis, three
general patterns of BRD4 dynamics were observed at gene pro-
moters: (1) increased BRD4 binding with PE, (2) loss of BRD4
binding with PE, and (3) constitutive BRD4 binding that is un-
changed by PE stimulation (Figure 6A). BRD4 binding to cardio-
myocyte promoters was significantly altered by miR-9 mimic
(Figure 6B). Indeed, ChIP-seq gene tracks illustrate PE-inducible
BRD4 binding to the promoters for the Nppa, Nppb, and Ctgf
genes, and reduction of BRD4 binding to these sites in cells
transfected with miR-9 mimic (Figure 6C). Consistent with the
SE analysis, BRD4 binding to the promoter of constitutively ex-
pressed Pln was unaffected by either PE or miR-9 (Figure 6D).
ChIP-PCR studies were next performed to test the hypothesis
that the miR-9-mediated reduction of BRD4 enrichment leads to
suppression of Pol II phosphorylation at corresponding TSSs.
NRVMs were transfected with miR-9 mimic or control mimic
and were either left unstimulated or stimulated with PE. After
48 hr of stimulation, ChIP was performed with an antibody spe-
cific for phospho-Ser-2 of the C-terminal domain of Pol II, which
reflects locus-specific enrichment for this elongating phospho-
form. DNA was analyzed by qPCR with primers flanking the
TSSs at the Nppa, Nppb, and Ctgf loci (Figure 7A). PE-mediated
Ser 2P-Pol II enrichment at these sites was significantly reduced
bymiR-9mimic (Figure 7B), consistent with the ability of miR-9 to
suppress agonist-mediated gene induction (see Figure 3F) and
BRD4 enrichment at associated SEs (Data S4). Together, these
findings suggest that miR-9 blunts signal-dependent patholog-
ical cardiac gene induction by repressing BRD4-dependent Pol
II phosphorylation and transcription elongation.DISCUSSION
The mechanisms by which stress stimuli are coupled to epige-
netic events that drive heart failure pathogenesis remain poorly
defined. Here, we describe a pathway for the inducible formation
of BRD4-enriched cardiomyocyte SEs, which function as signal-
integrating platforms to trigger pathological gene expression via
induction of Pol II phosphorylation. Signal-dependent targeting
of BRD4 to distinct genomic loci in cardiac muscle requires
HDAC-mediated downregulation of miR-9, establishing a role
for a microRNA in the genesis of SEs and in RNA Pol II activation
in the heart.
Our data suggest the presence of at least three pools of BRD4,
only one of which is significantly influenced by miR-9. Newly
accumulated, miR-9-regulatable BRD4 appears to be theon the x axis and ranked by log2 fold change upon PE treatment.
or PE-unchanged based on 1.5-fold change (induced, reduced) or <0.05-fold
ithout significantly altering binding to constitutive (unchanged) SEs.miR-9 also
in SEs. *p < 0.05.
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Figure 6. miR-9 Mimic Blunts Stimulus-Coupled Recruitment of BRD4 to Active Cardiomyocyte Promoters
(A) Promoters were defined in NRVMs based on Pol II and BRD4 co-occupancy. 420 BRD4-bound promoters are plotted on the x axis and ranked by log2-fold
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(B) BRD4-enriched active cardiomyocyte promoters are depicted in heatmap format. Red intensity indicates increased BRD4 signal relative to median intensity.
(C and D) Stimulus-coupled recruitment of BRD4 to SEs and promoters is illustrated by the BRD4 ChIP-seq tracks at the Nppb, Nppa, and Ctgf (C) gene loci.
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(C) A model for stimulus-dependent regulation of
pathological cardiac gene expression by miR-9
and BRD4.predominant form that is dynamically recruited to activated SEs
in response to a hypertrophic stimulus. In contrast, large peaks
of BRD4 on SEs associated with constitutively expressed genes
(e.g., Pln) are unaffected by miR-9, and signal-dependent
release of BRD4 from existing basal SEs is not blocked by
miR-9. Thus, miR-9 selectively blunts the augmented, signal-
induced pool of BRD4 that is targeted to SEs and promoters of
genes that are activated during pathological hypertrophy, rather
than functioning as a global suppressor of BRD4 function.
Signal-dependent formation of BRD4-enriched SEs in cardio-
myocytes is distinct from SE remodeling in endothelial cells
(Brown et al., 2014). In cardiomyocytes, increased abundance
of BRD4 in response to a hypertrophic agonist facilitates excess
loading of BRD4 onto SEs, whereas TNFa treatment of endothe-
lial cells leads to nuclear factor kB (NF-kB)-dependent redistri-
bution of BRD4 from basal SEs to de novo, stress-activated
SEs. Furthermore, endothelial cell activation results in a reduc-
tion in the overall number of SEs, while hypertrophic stimulation
of cardiomyocytes leads to a significant increase of BRD4-
bound SEs. Recruitment of BRD4 to discrete genomic loci in
cardiomyocytes likely involves associations with DNA binding
transcription factors and/or formation of an underlying histone
code that is preferentially bound by BRD4 (Brown et al., 2014;
Dey et al., 2003; Filippakopoulos et al., 2012; Hnisz et al.,1374 Cell Reports 16, 1366–1378, August 2, 20162015; Shi et al., 2014; Wu et al., 2013).
With regard to the former mechanism,
we have found that recruitment of BRD4
to SEs that lie upstream of the Ctgf TSS
is mediated, at least in part, by members
of the AP-1 family of transcription factors
(Figure 5). Further granularity on the
molecular underpinnings of dynamic SE
formation in the heart will accompany
delineation of additional components of
BRD4-enriched genomic complexes in
cardiomyocytes.
It is possible that BRD4 is controlled by
small RNA molecules other than miR-9.
For example, the abundance of an
150 kDa form of BRD4 was recently
shown to be influenced by miR-204 in
lung vascular smooth muscle cells (Me-loche et al., 2015). However, hypertrophic stimulation of cardio-
myocytes does not reduce miR-204 expression (Figure 1C),
arguing against a role for this non-coding RNA in the control of
BRD4 in the heart. It is intriguing to speculate that miR-9 target-
ing of BRD4 provides a generalizable mechanism for the regula-
tion of chromatin signaling that extends beyond heart muscle to
tissues such as brain, where both miR-9 and BRD4 serve crucial
roles in the control of neural gene expression (Korb et al., 2015;
Yuva-Aydemir et al., 2011).
The capacity of miRs tomodulate complex pathophysiological
processes, including heart failure, is attributed to their ability to
target broad collections of mRNAs (Olson, 2014; van Rooij and
Olson, 2012). As such, changes in cardiac gene expression eli-
cited by miR-9 are likely due to both BRD4-dependent and
BRD4-independent effects. In this regard, a miR-9 mimic was
shown to exhibit a high degree of efficacy and tolerability in a
mouse model of b-adrenergic receptor-mediated cardiac re-
modeling (Wang et al., 2010). Anti-hypertrophic activity of
miR-9 in this model was linked to reduced expression ofmyocar-
din, a transcriptional co-activator that promotes hypertrophy
through association with serum response factor (SRF) (Xing
et al., 2006). Although determination of the relative contribution
of SRF versus BRD4 downregulation to overall changes in car-
diac gene expression imparted by miR-9 awaits future study, it
is likely that BRD4 targeting by miR-9 influences a more wide-
ranging constellation of genes via effects on chromatin signaling
and Pol II dynamics. This notion is supported by the similarity in
transcriptome-wide gene expression changes in cardiomyo-
cytes treated with miR-9 mimic or the small molecule BET inhib-
itor, JQ1 (Figure 3E).
Fibrosis is another key component of heart failure, and it
should be noted that many of the BRD4-enriched SEs we iden-
tified in cardiomyocytes are associated with pro-fibrotic genes,
including those encoding the secreted factors CTGF, plasmin-
ogen activator inhibitor-1 (PAI-1/Serpine1) and transforming
growth factor beta-2 (TGF-b2) (Data S4). These findings suggest
the possibility that miR-9/BRD4 signaling in cardiomyocytes reg-
ulates expression of paracrine factors that crosstalk with fibro-
blasts in the heart to elicit fibrotic remodeling. Furthermore, the
prospect of miR-9/BRD4 directly regulating pro-fibrotic gene
expression in cardiac fibroblasts warrants future consideration,
especially in light of the recent discovery that miR-9 exhibits
anti-fibrotic effects in the lung (Fierro-Ferna´ndez et al., 2015).
Our prior studies demonstrated that general BET inhibition
with JQ1 blocks Pol II phosphorylation and transcriptional pause
release of Pol II in response to pathological stress in the heart
(Anand et al., 2013; Spiltoir et al., 2013). Here, we provide evi-
dence of a molecular circuit for stress-dependent control of
Pol II dynamics at TSSs of genes that promote adverse cardiac
remodeling. The circuit is activated upon signal- and HDAC-
dependent repression of miR-9, which enables BRD4 enrich-
ment at SEs and promoters of pro-hypertrophic genes and leads
to subsequent Pol II phosphorylation and transcription elonga-
tion (schematized in Figure 7C). Manipulation of this chromatin
signaling axis may provide an innovative avenue for the treat-
ment of cardiovascular disease.EXPERIMENTAL PROCEDURES
RNA-Seq and ChIP-Seq
RNA was isolated from NRVMs using the High Pure RNA Isolation Kit (Roche).
RNA was submitted to the WITG for library preparation (TruSeq Stranded
mRNA Library Prep Kit, Illumina) and sequencing (HighSeq 2500). All RNA
sample had 260/280 ratios above 2.1 and Rin scores above 8. ChIP was con-
ducted with cultured NRVMs as previously reported (Anand et al., 2013).
Detailed descriptions of the methods employed for ChIP and for analysis of
RNA-seq and ChIP-seq data are described below.
ChIP and ChIP-Seq
Chromatin was crosslinked in 1% PFA for 10 min and unreacted PFA was
neutralized with glycine for 5 min, washed with ice cold PBS, and harvested
in PBS with protease and phosphatase inhibitors (Halt). NRVM pellets were
snap frozen and stored at 80C until processed. Pellets were re-suspended
in lysis buffer 1 (50 mM HEPES, 140 mM NaCl, 1 mM EDTA, 10% glycerol,
0.5% NP40, 0.25% Triton X-100) and rotated for 15 min at 4C. After centrifu-
gation, pellets were then re-suspended in lysis buffer 2 (10 mM Tris HCl,
200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA) and rotated for 5 min at 4C. After
centrifugation, pellets were re-suspended in shearing buffer (50 mM HEPES,
140 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% TX100, 0.1% sodium deoxycho-
late, 1% SDS) and sheared using a Diagenode Bioruptor (15 min, 30 s on/30 s
off, setting high). Cleared chromatin was then immunoprecipitated with 5 mg of
antibody attached to protein G Dynabeads (Invitrogen). Thirty million cells
were used per ChIP for BRD4 (Bethyl, A301-985A) ChIP-seq and 15,000,000
cells were used per ChIP for RNA Pol II (Santa Cruz N-20, sc-899) ChIP-seq.
Following overnight immunoprecipitation (IP), beads were washed fivetimes and DNA was eluted in 50 mM Tris HCl, 10 mM EDTA, and 1% SDS so-
lution at 65C for 15 min. Following reversal of crosslinks, RNase, and protein-
ase treatment, DNA was purified using the MinElute PCR Purification kit
(QIAGEN). Minor modifications were made to the above protocol for ChIP
qPCR investigation of RNA Pol II phosphorylation on serine 2 (Abcam,
ab24758). ChIP-seq DNA was submitted to WITGC for library preparation
(TruSeq ChIP Sample Prep Kit for ChIP-Seq, Illumina) and sequencing
(HighSeq 2500).
Sequencing Data Analysis
All analysis was performed using Rat RN4 genome and RN4 RefSeq gene
annotations. Raw and processedChIP-seq and RNA-seq data were deposited
to the GEO online database (http://www.ncbi.nlm.nih.gov/geo/) under acces-
sion numbers GEO: GSE82243 and GSE83228.
RNA-Seq Processing
All RNA-seq datasets were aligned to the transcriptome using Tophat2
(version 2.0.11) (http://www.genomebiology.com/2013/14/4/R36/abstract).
Gene expression values were quantified using Cufflinks and Cuffnorm (version
2.2.0) (Trapnell et al., 2010).
ChIP-Seq Processing
All ChIP-seq datasets were aligned using Bowtie2 (version 2.2.1) to build
version RN4 of the rat genome (Langmead and Salzberg, 2012). Alignments
were performed using the following criteria: -k 1. These criteria preserved
only reads that mapped uniquely to the genome. ChIP-seq read densities
were calculated the normalized using Bamliquidator (https://github.com/
BradnerLab/pipeline/wiki/Bamliquidator). Briefly, ChIP-seq reads aligning to
the region were extended by 200 base pairs (bp) and the density of reads
per bp was calculated. The density of reads in each region was normalized
to the total number of million mapped reads producing read density in units
of reads per million mapped reads per bp (rpm/bp). MACS version 1.4.2
(model-based analysis of ChIP-seq) peak finding algorithm was used to iden-
tify regions of ChIP-seq enrichment over background (Zhang et al., 2008).
A p value threshold of enrichment of 1e-9 was used for all datasets. A gene
was defined as actively transcribed if enriched regions for RNA polymerase
II (RNA Pol II) were located within ±1 kb of the TSS.
Mapping and Comparing Enhancers and Super-Enhancers
BRD4 ChIP-seq data were used to identify active cis-regulatory elements in
the genome. ROSE2 (https://github.com/bradnerlab/pipeline/) was used to
identify BRD4 enhancers and super-enhancers as in Brown et al. (2014).
Briefly, proximal regions of BRD4 enrichment were stitched together if within
2 kb of one another. This 2 kb stitching parameter was determined by
ROSE2 as the distance that optimally consolidated the number of discreet en-
riched regions in the genome while maintaining the largest fraction of enriched
bases per region. Comparison of BRD4 changes at enhancers, super-en-
hancers, and promoter regions was performed as previously described (Brown
et al., 2014). Active genes within 50 kb of enhancer regions were assigned as
target genes, as described previously (Brown et al., 2014).
Transcription Factor Binding Site Analysis
Genomic DNA sequences of BRD4 SEs from the RN4 reference genome were
searched for TF binding sites using LASAGNA 2.0. Reference TF binding sites
were taken from the Citrome server, Encode, and the Transfac database.
qPCR
For assessment ofmiR expression, cDNAwas prepared usingmiScript II RT kit
(Hi Flex buffer option, QIAGEN) from Trizol-isolated RNA. qPCR was accom-
plished with miScript SYBR Green PCR kit (QIAGEN) using a StepOnePlus
Real-Time PCR System (Life Technologies). For assessment of pathological
hypertrophy markers, cDNA was prepared using Verso cDNA Synthesis Kit
(Life Technologies) from Trizol-isolated RNA. qPCR was accomplished with
DyNAmo Flas SYBR Green qPCR kit (Life Technologies) using a StepOnePlus
Real-Time PCR System (Life Technologies). Primer sequences are shown in
Table S1. Sham and TAC LVs, Nx, and Hypoxia + SU5416 RVs, and human
pre- and post-LVAD samples have been previously described (AmbardekarCell Reports 16, 1366–1378, August 2, 2016 1375
et al., 2011; Cavasin et al., 2014; Spiltoir et al., 2013; Stratton and McKinsey,
2015; Weitzel et al., 2013). Relative gene expression was calculated using
the –DDCt method with normalization to 18S.
Protein Analysis
Protein lysates were prepared in RIPA buffer containing Halt Protease Phos-
phatase Inhibitor cocktail (ThermoScientific; 1861280). Cells were sonicated
prior to clarification by centrifugation. Protein concentrations were deter-
mined using a BCA Protein Assay Kit (Thermo Scientific). Proteins were
resolved by SDS-PAGE, transferred to nitrocellulose membranes (Life Sci-
ence Products) and probed with primary antibodies specific for calnexin
(Santa Cruz Biotechnology, sc-11397), BRD2 (Cell Signaling Technology;
#5848), BRD4 (Bethyl Laboratories, A301-985A; Ab #1), or BRD4 (Abcam,
ab128874; Ab #2). Proteins were detected using SuperSignal West Pico
Chemiluminescent Substrate (ThermoScientific; 34080) and a FluorChem
HD2 Imager (Alpha Innotech). The Colorado Multicenter Institutional Review
Board approved the protocol for the collection, storage, and analysis of hu-
man tissue.
Luciferase Assays
The 30UTR of rat BRD4 was PCR-amplified from NRVM cDNA and cloned into
the pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega).
Mutant BRD4 30 UTR was generated by site-directed mutagenesis PCR.
One microgram of reporter construct and miR mimic (25 nM final concentra-
tion) was transfected into HEK293 cells using LIPO3000 transfection reagent.
After 24 hr, cells were harvested and assayed using the Dual-Luciferase
Reporter Assay System (Promega). Luciferase/Renilla activity was measured
on a Glomax 20/20 Luminometer.
NRVM Isolation, Culture, and Adenovirus Infection
Neonatal rat ventricular myocytes (NRVMs) were isolated from the hearts of 1-
to 3-day-old Sprague-Dawley rats (Charles River), as previously described
(Simpson et al., 1989). Cell counting and viability was assayed using a Vi-
Cell Cell Viability Analyzer (Beckman Coulter). Cells were incubated overnight
on 10-cm plates coated with 0.2% gelatin (Sigma-Aldrich; G9391) in DMEM
with 5% calf serum, 2 mM L-glutamine, and penicillin-streptomycin. The
followingmorning, cells were washedwith serum-freemedium andmaintained
in DMEM supplemented with L-glutamine, penicillin-streptomycin, and Neutri-
doma-SP (0.1%; Roche Applied Science), which contains albumin, insulin,
transferrin, and other defined organic and inorganic compounds. For all
studies, cells were treated in maintenance media for 48 hr in the absence or
presence of agonists. PE, PGF2a, and AR-42 were obtained from Sigma,
Enzo Life Sciences, and Selleckchem, respectively.
NRVMs were treated with the following miR mimics, miR inhibitors, and
siRNAs: miRIDIAN microRNA Rat rno-miR-9a-5p Mimic (Dharmacon),
miRIDIAN microRNA Rat rno-miR-9a-5p–Hairpin Inhibitor (Dharmacon),
miRIDIAN microRNA Hairpin Inhibitor Negative Control #2 (Dharmacon)
mission siRNA for BRD4 SASI_RN02_00315747 (Sigma Aldrich), and mission
siRNA Universal Negative Control #1 (Sigma-Aldrich).
Adenoviruses encoding dnAP-1, shBRD4, and shControl were previously
described (Anand et al., 2013; Olive et al., 1997). NRVMs were infected at
the time of plating with a multiplicity-of-infection of 50, and washed after over-
night incubation.
Quantification of NRVM Cell Size
NRVM images were captured on the EVOS FL Cell Imaging System (Thermo
Fisher Scientific). Cell size was quantified in Image J by a researcher blinded
to treatment group. Each treatment group contained three independent plates
of NRVMs. Two fields of view per plate were selected at random and four cells
per field were measured after size calibration.
Statistical Analysis
All data (except RNA-seq and ChIP-seq) were analyzed with GraphPad Prism
using either t tests (unpaired, two-tailed) when two variables were present, or
ANOVA (one-way with posthoc) when three variables were present. Error bars
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